Loading
A phase 1/2 trial of ORIC-114 in advanced solid tumours, run by ORIC Pharmaceuticals, now recruiting.
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration is a phase 1/2 interventional study registered as NCT05315700 by ORIC Pharmaceuticals, with 350 participants planned, started 2022-03-10 and due to reach its primary completion in 2026-09. Interventions recorded: ORIC-114 and Chemotherapy drug.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/